BASEL, Switzerland, March 5, 2025 /PRNewswire/ -- Following its 16 July 2024 announcement, CordenPharma is pleased to share significant progress on its growth initiatives with a >€1 billion ...

NBE Therapeutics CEO Jean Engela stated: "This investment in a new, cutting-edge research centre underscores our strong ...

Today NBE Therapeutics (NBE) a wholly owned subsidiary of Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel. This milestone reinforces its commitment to innovation in oncology ...

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug ...

and large peptide manufacturing facilities across Europe and the US. In Switzerland, CordenPharma will invest >€500m to construct a greenfield site for small to large-scale peptide development and ...